Ayala Pharmaceuticals Stock Forecast, Price & News

Ayala Pharmaceuticals (NASDAQ:AYLA) Frequently Asked Questions

Is Ayala Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ayala Pharmaceuticals stock.
View analyst ratings for Ayala Pharmaceuticals or view top-rated stocks.

When is Ayala Pharmaceuticals' next earnings date?

Ayala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Ayala Pharmaceuticals.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.12. The business earned $0.63 million during the quarter, compared to the consensus estimate of $0.82 million. Ayala Pharmaceuticals had a negative trailing twelve-month return on equity of 91.26% and a negative net margin of 1,177.26%.
View Ayala Pharmaceuticals' earnings history.

What price target have analysts set for AYLA?

5 equities research analysts have issued 12 month target prices for Ayala Pharmaceuticals' stock. Their forecasts range from $17.00 to $29.00. On average, they anticipate Ayala Pharmaceuticals' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 136.7% from the stock's current price.
View analysts' price targets for Ayala Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Ayala Pharmaceuticals' key executives?

Ayala Pharmaceuticals' management team includes the following people:

• Dr. Roni Mamluk, Pres, CEO & Director (Age 54, Pay $635.6k)
• Mr. Yossi Maimon CPA, M.B.A., CPA, MBA, CFO, Sec. & Treasurer (Age 50, Pay $692.18k)
• Dr. Gary B. Gordon M.D., Ph.D., Chief Medical Officer (Age 68, Pay $550.31k)

Who are some of Ayala Pharmaceuticals' key competitors?

Some companies that are related to Ayala Pharmaceuticals include Precision BioSciences (DTIL), Tarsus Pharmaceuticals (TARS), Talaris Therapeutics (TALS), Aura Biosciences (AURA), Graphite Bio (GRPH), Ikena Oncology (IKNA), Taysha Gene Therapies (TSHA), Aerie Pharmaceuticals (AERI), Athira Pharma (ATHA), SAB Biotherapeutics (SABS), Autolus Therapeutics (AUTL), Poseida Therapeutics (PSTX), Curis (CRIS), Molecular Partners (MOLN) and CEL-SCI (CVM).
View all of AYLA's competitors.

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Moderna (MRNA), CrowdStrike (CRWD), Dynavax Technologies (DVAX), Square (SQ), Abbott Laboratories (ABT), Alpine Immune Sciences (ALPN), Advanced Micro Devices (AMD), BioLineRx (BLRX), Cognex (CGNX) and Micron Technology (MU).

When did Ayala Pharmaceuticals IPO?

(AYLA) raised $50 million in an initial public offering on Friday, May 8th 2020. The company issued 3,300,000 shares at $14.00-$16.50 per share. Citigroup and Jefferies served as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers.

What is Ayala Pharmaceuticals' stock symbol?

Ayala Pharmaceuticals trades on the NASDAQ under the ticker symbol "AYLA."

Who are Ayala Pharmaceuticals' major shareholders?

Ayala Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (7.26%). Company insiders that own Ayala Pharmaceuticals stock include Gary B Gordon and Roni Mamluk.
View institutional ownership trends for Ayala Pharmaceuticals.

Which major investors are buying Ayala Pharmaceuticals stock?

AYLA stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP.
View insider buying and selling activity for Ayala Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Ayala Pharmaceuticals?

Shares of AYLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ayala Pharmaceuticals' stock price today?

One share of AYLA stock can currently be purchased for approximately $10.14.

How much money does Ayala Pharmaceuticals make?

Ayala Pharmaceuticals has a market capitalization of $141.30 million and generates $3.71 million in revenue each year. The company earns $-30.15 million in net income (profit) each year or ($2.90) on an earnings per share basis.

How many employees does Ayala Pharmaceuticals have?

Ayala Pharmaceuticals employs 34 workers across the globe.

What is Ayala Pharmaceuticals' official website?

The official website for Ayala Pharmaceuticals is www.ayalapharma.com.

Where are Ayala Pharmaceuticals' headquarters?

Ayala Pharmaceuticals is headquartered at Oppenheimer 4, Rehovot L3, 7670104.

How can I contact Ayala Pharmaceuticals?

Ayala Pharmaceuticals' mailing address is Oppenheimer 4, Rehovot L3, 7670104. The company can be reached via phone at 857-444-0553 or via email at [email protected].